
    
      Liver cancer is one of the most common malignancies in China, ranking fourth in all malignant
      tumors and third in mortality. Immunetherapy is considered to be one of the most promising
      means of human against cancer. This is a phase II clinical trial of single-center, randomized
      (1:1of targeted activation CIK and traditional CIK therapy )comparison clinical trial of
      activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver
      cancer. The investigators plan to recruit for 80 cases patients with advanced liver cancer,
      the first 20 cases were directly received treatment of activated CIK, and the cases after the
      20th were randomly assigned to two groupï¼Œone of the two group will receive treatment of
      traditional CIK, and the other receive activated CIK. The result of this study was statistic
      and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1)
      evaluation standard.
    
  